SNSE: רווח נקי למניה (EPS TTM) Sensei Bio

The development of the Immuno-Phage platform by Sensei Biotherapeutics (SNSE) is independent of economic cycles, as demonstrated by the trailing 12-month net income per share. The level of -18.97 represents the current value of this metric. Fundamentally, the business relies on capital raising due to a lack of sales and the risks of clinical antibody test failures, leaving the company dependent on new equity offerings.

Sensei Biotherapeutics (SNSE) operates as a small-cap biotech with minimal environmental impact, focusing on laboratory research. The specific nature of the clinical trial stage results in a lack of large-scale revenues, which directly impacts the calculation of net income distributed per share. This trailing twelve-month (TTM) metric measures the final business efficiency, adjusted for the volume of issuance. By analyzing the TTM earnings per share (EPS), an investor assesses the financial stability of Sensei Biotherapeutics (SNSE) during periods of market volatility. The TTM EPS trend allows for the identification of the model's adaptability to development costs.